Mobile

A multinational, multicenter, single visit, exploratory pharmacogenetic trial and long-term follow-up of the PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multi...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-015502-19

A multinational, multicenter, single visit, exploratory pharmacogenetic trial and long-term follow-up of the PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) trial

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To analyze the association between single nucleotide polymorphism (SNP) markers and treatment response. Treatment response is based on the Expanded Disability Status Scale (EDSS) progression and relapse outcomes over the first 2 years of treatment in the PRISMS trial.

Critère d'inclusion

  • Multiple sclerosis

Liens